The short answer: Mostly, yes, but not every pill matches every shot. The 25 mg Wegovy pill produced 13.6% average weight loss in its main trial, close to the 14.9% seen with weekly Wegovy injections. Orforglipron (Foundayo) produced about 11%, and weekly tirzepatide injections produced up to 20.9%. These figures come from separate trials, so treat them as a rough guide, not a head-to-head result.

Which GLP-1 pills does the FDA approve in 2026?

Three oral products are on the U.S. market, and they are not all the same drug.

  • Rybelsus and Ozempic tablets (oral semaglutide). These treat type 2 diabetes. The current FDA label, revised January 2026, lists Ozempic tablets in 1.5 mg, 4 mg and 9 mg strengths. They are not approved for weight loss.
  • Wegovy pill (oral semaglutide 25 mg). The FDA approved it on December 22, 2025, for weight loss and to lower the risk of major cardiovascular events, per Novo Nordisk. The Wegovy label lists 1.5, 4, 9 and 25 mg tablets, with 25 mg daily as the maintenance dose.
  • Foundayo (orforglipron). The FDA approved it on April 1, 2026, for adults with obesity, or overweight with a weight-related condition, per Eli Lilly. It is a small-molecule drug, not a peptide like semaglutide.

For the full lineup, including the injectables, see our GLP-1 medications comparison.

How much weight do people lose on pills compared with shots?

Each drug had its own large placebo-controlled trial. The numbers below use each trial's main analysis, which counts everyone who was randomized, including people who stopped the drug.

  • Wegovy pill, 25 mg daily: 13.6% average loss at 64 weeks vs 2.2% on placebo in the OASIS 4 trial (307 adults).
  • Wegovy injection, 2.4 mg weekly: 14.9% at 68 weeks vs 2.4% on placebo in STEP 1 (1,961 adults).
  • Foundayo, highest dose: 11.2% at 72 weeks vs 2.1% on placebo in ATTAIN-1 (3,127 adults). The Foundayo label reports 11.1% for its top 17.2 mg dose.
  • Tirzepatide injection, 15 mg weekly: 20.9% at 72 weeks vs 3.1% on placebo in SURMOUNT-1 (2,539 adults).

Novo Nordisk reports 16.6% average loss among OASIS 4 participants who kept taking the pill. The company calls this similar to injectable Wegovy. The main results support that: 13.6% and 14.9% sit close together. Foundayo lands a few points lower. Tirzepatide remains the strongest option in either form.

Keep the limits in mind. The trials enrolled different people, ran for different lengths of time and used slightly different methods. No published trial has put the Wegovy pill directly against the Wegovy shot, or any pill against tirzepatide.

How do pills and shots compare for blood sugar?

For type 2 diabetes, oral semaglutide has the longest track record. The Rybelsus prescribing information reports these 26-week results:

  • As the only diabetes drug, 14 mg daily lowered A1C by 1.4 points vs 0.3 on placebo. 77% of patients reached an A1C under 7%.
  • Added to metformin, 14 mg daily lowered A1C by 1.2 points. Daily liraglutide injections (1.8 mg) lowered it by 1.1 points. The pill was noninferior to the shot.

That second trial is the closest pill-versus-shot comparison on the label. Liraglutide is an older daily injection, though, not weekly Ozempic.

The main head-to-head trial between two pills is ACHIEVE-3, published in The Lancet in February 2026. It followed 1,698 adults on metformin for 52 weeks. Orforglipron at its highest trial dose lowered A1C by 2.2 points vs 1.4 points for oral semaglutide 14 mg, according to Eli Lilly. Weight loss was 9.2% vs 5.3%. The trial was open-label and funded by Lilly.

Why does oral semaglutide come with strict dosing rules?

Semaglutide is a peptide, and the gut breaks most of it down. The Rybelsus label estimates that only about 0.4% to 1% of an oral dose reaches the bloodstream. That is why the daily pill dose (25 mg for weight loss) is much higher than the weekly injection dose (2.4 mg). The tablet also contains an absorption enhancer called SNAC.

Food and drink cut absorption further. The Wegovy tablet and Rybelsus and Ozempic tablet labels set the same rules:

  1. Take one tablet on an empty stomach in the morning.
  2. Swallow it whole with no more than 4 ounces of plain water. Do not use any other liquid.
  3. Wait at least 30 minutes before you eat, drink or take other oral medicines.

The Rybelsus label says a shorter wait, food or other drinks will lessen the effect by decreasing absorption. The label also reports that levothyroxine exposure rose 33% when taken with semaglutide tablets. Foundayo is different. Its label says to take it once daily with or without food, and Lilly says any time of day works.

Do pills cause different side effects than shots?

The side effects look much the same, because all these drugs act on the same receptor. Nausea, diarrhea, vomiting and constipation lead the list, mostly during dose increases.

  • In OASIS 4, 74.0% of people on the Wegovy pill had a digestive side effect vs 42.2% on placebo.
  • In ATTAIN-1, 5.3% to 10.3% of people on orforglipron stopped because of side effects vs 2.7% on placebo.
  • In SURMOUNT-1, 4.3% to 7.1% stopped tirzepatide injections because of side effects vs 2.6% on placebo.
  • In STEP 1, 4.5% stopped semaglutide injections because of digestive side effects vs 0.8% on placebo.

In ACHIEVE-3, more people stopped orforglipron (8.7% to 9.7%) than oral semaglutide (4.5% to 4.9%) because of side effects. The Rybelsus and Foundayo labels both carry a boxed warning about thyroid C-cell tumors seen in rodents. For the full picture, see our GLP-1 side effects guide.

Who might do better with a pill than a shot?

The best drug is often the one a person can keep taking. A pill may suit people who dislike needles or who find a daily tablet easier to remember. Foundayo may fit people who cannot keep a fasting routine, since it has no food or water rules. The oral semaglutide routine can be hard for people who take several morning medicines.

A shot may suit people who want the largest average weight loss, since tirzepatide injections led the trials. It may also suit people who prefer one dose a week. The Ozempic tablet label lets people on 0.5 mg Ozempic injections switch to 4 mg or 9 mg tablets one week after their last shot. For semaglutide-specific detail, ozempic.md covers Ozempic in both forms. Prices and coverage differ by product and plan, so check our GLP-1 cost and insurance guide.

The bottom line

The 25 mg Wegovy pill comes close to the Wegovy shot for weight loss, about 13.6% vs 14.9% in separate trials. Foundayo trails at about 11%, but it has no fasting rules. Tirzepatide injections still produce the largest average loss. Oral semaglutide works only if you follow the empty-stomach, small-sip, 30-minute routine. Ask your prescriber which form fits your health, schedule and budget.

Last updated: September 2026. This article is for informational purposes only and does not constitute medical advice. Talk with your doctor before you start, stop or switch any GLP-1 medication.